alexa HER2-Targeted Antibody Treatment for Ovarian Cancer Fut
ISSN: 2329-9053

Journal of Molecular Pharmaceutics & Organic Process Research
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Editorial

HER2-Targeted Antibody Treatment for Ovarian Cancer Future Opportunities

Simon P Langdon1* and Andrew H Sims2

1Division of Pathology, Institute of Genetics and Molecular Medicine, University of Edinburgh, Crewe Road South, Edinburgh EH4 2XU, United Kingdom

2University of Edinburgh Cancer Research Centre, Institute of Genetics and Molecular Medicine, University of Edinburgh, Crewe Road South, Edinburgh EH4 2XU, United Kingdom

*Corresponding Author:
Langdon SP
Division of Pathology, Institute of Genetics and Molecular Medicine
University of Edinburgh, Crewe Road South, Edinburgh EH4 2XU, United Kingdom
Tel: 0131 537 1763
E-mail: [email protected]

Received date: June 21, 2016; Accepted date: June 23, 2016; Published date: June 27, 2016

Citation: Langdon SP, Andrew H Sims (2016) HER2-Targeted Antibody Treatment for Ovarian Cancer – Future Opportunities. J Mol Pharm Org Process Res 4:e125. doi:10.4172/2329-9053.1000e125

Copyright: © 2016 Langdon SP, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

 

Abstract

There are an estimated 240,000 new cases of ovarian cancer diagnosed worldwide each year [1]. Due to late presentation, in many parts of the world it remains the most lethal gynecological cancer [2]. In 2004, a new model description of this disease was proposed that combined both histopathological and molecular features and which classified epithelial ovarian cancers into two broad categories designated Type I and Type II tumors [3].

Share This Page

Additional Info

Loading
Loading Please wait..
 
Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords